FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Marketing

FDA Cites Sanofi Over Misleading Beyfortus Promotional Emails

FDA sends an untitled letter to Sanofi Vaccines U.S., alleging that promotional emails for its respiratory syncytial virus prevention product Beyfortu...

latest-news-card-1

Novo Nordisk Sues Lilly Over GLP-1 Ads

Novo Nordisk sues Lilly in New Jersey federal court over what the company says is a misleading national ad campaign that compares the two companies GL...

latest-news-card-1
Human Drugs

No Informed Consent in Alembic Trial

FDA warns Indias Alembic Research Center that it failed to obtain informed consent for an in vivo bioequivalence study.

latest-news-card-1
Human Drugs

Make Better Use of 505(b)(2) Pathway: Column

Two InnoDev Partners consultants urge industry to re-embrace the 505(b)(2) approval pathway in instances in which it can save drug development time an...

latest-news-card-1
FDA General

FDA Reform Requires a Whole-of-System Strategy: Editorial

A Cureus Journal of Medical Science open-source editorial calls for a rebuilding of the U.S. scientific infrastructure as the only way to successfully...

latest-news-card-1
FDA General

House Passes FDA Modernization Act 3.0 for Reducing Animal Testing

The U.S. House of Representatives passes the FDA Modernization Act 3.0 (H.R. 2821), advancing bipartisan legislation intended to accelerate the adopti...

latest-news-card-1
Human Drugs

Acadia Gets Fast Track for Alzheimers Psychosis Drug

FDA awards Acadia Pharmaceuticals a Fast Track designation for remlifanserin, an investigational, highly selective, 5-HT2A receptor inverse agonist fo...

latest-news-card-1
Human Drugs

CGMP Issues at Indias Shimoga Chemicals

FDA warns Indias Shimoga Chemicals about CGMP deviations in its production of active pharmaceutical ingredients.

latest-news-card-1
Human Drugs

China Surpasses U.S. in Novel Cancer Drug Approvals Since 2023: Analysis

China approves more novel oncology drugs than the U.S. between 2020 and 2025, with its annual approval totals surpassing FDAs beginning in 2023, accor...

latest-news-card-1
Biologics

Dyne Therapeutics BLA for Duchenne Muscular Dystrophy

FDA accepts for priority review a Dyne Therapeutics BLA for zeleciment rostudirsen for treating individuals with Duchenne muscular dystrophy amenable ...